array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Novartis Gene Therapies, Inc."
["slug"]=>
string(19) "a26d9-us-avexis-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/35cea00f-69c0-468d-b166-ddd4f49dfa0c"
["description"]=>
string(639) "Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP"
["address_street"]=>
string(24) "2275 Half Day Rd Ste 200"
["address_place"]=>
string(11) "Bannockburn"
["address_region"]=>
string(8) "Illinois"
["founding_date"]=>
string(10) "2010-02-28"
["website_domain"]=>
string(12) "novartis.com"
["website_url"]=>
string(24) "https://www.novartis.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(219)
["article_count"]=>
int(7824)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(127) "EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis"
["snippet_en"]=>
string(127) "EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis"
["url"]=>
string(170) "https://www.sharewise.com/de/news_articles/EQSNews_MorphoSys_Management_Board_and_Supervisory_Board_Recommend_Shareholders_Accept_Public_Tak_Morphosys_eqsen_20240411_1238"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/7ba6842e-7ec6-426f-87d8-6ea15c611b21"
["source"]=>
string(13) "sharewise.com"
["publication_date"]=>
string(10) "2024-04-11"
["categories"]=>
array(5) {
[0]=>
string(12) "Board Change"
[1]=>
string(21) "Shareholders Feedback"
[2]=>
string(6) "Merger"
[3]=>
string(11) "Acquisition"
[4]=>
string(20) "Corporate Governance"
}
}
[1]=>
array(7) {
["title_en"]=>
string(52) "Novartis takeover offer recommended by Morphosys top"
["snippet_en"]=>
string(202) "The takeover offer from Novartis to the German drug researcher Morphosys was met with approval. The board of directors and supervisory board of Morphosys have recommended acceptance to the shareholders."
["url"]=>
string(97) "https://www.cash.ch/news/top-news/novartis-ubernahmeangebot-von-morphosys-spitze-empfohlen-701566"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c582dcd8-442b-4476-a00a-13c93a9a731e"
["source"]=>
string(7) "cash.ch"
["publication_date"]=>
string(10) "2024-04-11"
["categories"]=>
array(4) {
[0]=>
string(12) "Board Change"
[1]=>
string(11) "Acquisition"
[2]=>
string(20) "Corporate Governance"
[3]=>
string(6) "Merger"
}
}
[2]=>
array(7) {
["title_en"]=>
string(126) "EQS News: The Executive Board and Supervisory Board of MorphoSys recommend acceptance of the public takeover offer by Novartis"
["snippet_en"]=>
string(105) "EQS-News: MorphoSys AG / Keyword(s): Mergers & Acquisitions/SalesBoard of Directors and Supervisory Board"
["url"]=>
string(64) "https://www.4investors.de/nachrichten/dgap-meldung.php?ID=136378"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/59300142-7272-4a28-8181-f3136dc0afd3"
["source"]=>
string(13) "4investors.de"
["publication_date"]=>
string(10) "2024-04-11"
["categories"]=>
array(4) {
[0]=>
string(12) "Board Change"
[1]=>
string(11) "Acquisition"
[2]=>
string(20) "Corporate Governance"
[3]=>
string(6) "Merger"
}
}
[3]=>
array(7) {
["title_en"]=>
string(48) "Novartis Tender Offer for MorphoSys AG Commences"
["snippet_en"]=>
string(170) "Novartis published the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG."
["url"]=>
string(151) "https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/pharma-finance-and-investment-news/novartis-tender-offer-for-morphosys-ag-commences/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/d6a99310-7e6f-4f8e-b201-7b6b015baeb9"
["source"]=>
string(32) "pharmaceuticalmanufacturer.media"
["publication_date"]=>
string(10) "2024-04-01"
["categories"]=>
array(5) {
[0]=>
string(15) "Deals & Tenders"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(6) "Merger"
[3]=>
string(12) "Stock Market"
[4]=>
string(11) "Acquisition"
}
}
[4]=>
array(7) {
["title_en"]=>
string(51) "Acquisition of MorphoSys AG by Novartis AG approved"
["snippet_en"]=>
string(209) "The Federal Cartel Office has approved the planned takeover of all shares in MorphoSys AG, based in Planegg near Munich, by Novartis AG (Switzerland) in the preliminary review process under merger control law."
["url"]=>
string(127) "https://www.finanznachrichten.de/nachrichten-2024-03/61662639-erwerb-der-morphosys-ag-durch-die-novartis-ag-freigegeben-019.htm"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/351d4d87-5e73-429f-bf8a-316ccb7a7bf0"
["source"]=>
string(20) "finanznachrichten.de"
["publication_date"]=>
string(10) "2024-03-12"
["categories"]=>
array(3) {
[0]=>
string(24) "Government Interventions"
[1]=>
string(11) "Acquisition"
[2]=>
string(6) "Merger"
}
}
[5]=>
array(7) {
["title_en"]=>
string(63) "Antitrust Policy and Legal Standards for Build-or-Buy Decisions"
["snippet_en"]=>
string(298) "By Jay Ezrielev1 I. Introduction The newly finalized U.S. Department of Justice( DOJ) and the Federal Trade Commission( FTC) Merger Guidelines have excluded one of the most controversial statements of the draft Merger Guidelines.2 That statement is:“ The antitrust laws reflect a preference for"
["url"]=>
string(97) "https://www.pymnts.com/cpi_posts/antitrust-policy-and-legal-standards-for-build-or-buy-decisions/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/0bf6ebe5-4774-4df8-b682-77c8e6b935c1"
["source"]=>
string(10) "pymnts.com"
["publication_date"]=>
string(10) "2024-02-29"
["categories"]=>
array(5) {
[0]=>
string(5) "Legal"
[1]=>
string(9) "Antitrust"
[2]=>
string(11) "Regulations"
[3]=>
string(6) "Merger"
[4]=>
string(21) "Competitive Behaviour"
}
}
[6]=>
array(7) {
["title_en"]=>
string(75) "Hot takeover speculation: 5 stocks whose companies could soon be taken over"
["snippet_en"]=>
string(165) "After Novartis's takeover offer to Morphosys, other German companies could find themselves in the sights of corporate hunters. BÖRSE ONLINE presents five candidates"
["url"]=>
string(153) "https://www.boerse-online.de/nachrichten/aktien/heisse-uebernahme-spekulationen-5-aktien-deren-unternehmen-bald-uebernommen-werden-koennten-20350550.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/535fa637-7ee1-4a64-8a25-f9a2f3815d35"
["source"]=>
string(16) "boerse-online.de"
["publication_date"]=>
string(10) "2024-02-16"
["categories"]=>
array(2) {
[0]=>
string(11) "Acquisition"
[1]=>
string(6) "Merger"
}
}
[7]=>
array(7) {
["title_en"]=>
string(57) "More pharma M&A as Novartis snaps up MorphoSys for $2.9bn"
["snippet_en"]=>
string(112) "Novartis has agreed to buy Germany's MorphoSys in a transaction that values the cancer-focused biotech at $2.9bn"
["url"]=>
string(74) "https://pharmaphorum.com/news/more-pharma-ma-novartis-snaps-morphosys-29bn"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/bb4c0486-b613-4e59-814f-4159ef69bf10"
["source"]=>
string(16) "pharmaphorum.com"
["publication_date"]=>
string(10) "2024-02-06"
["categories"]=>
array(2) {
[0]=>
string(11) "Acquisition"
[1]=>
string(6) "Merger"
}
}
[8]=>
array(7) {
["title_en"]=>
string(64) "MorphoSys rises 37% amid rumors of possible takeover by Novartis"
["snippet_en"]=>
string(152) "Drugmaker Novartis AG ( NOVN.CH ) is in advanced talks to take over MorphoSys AG ( MOR.DE ), two people familiar with the matter told Reuters on Monday."
["url"]=>
string(49) "https://www.fxstreet.cz/zpravodajstvi-155420.html"
["image_url"]=>
NULL
["source"]=>
string(11) "fxstreet.cz"
["publication_date"]=>
string(10) "2024-02-05"
["categories"]=>
array(2) {
[0]=>
string(11) "Acquisition"
[1]=>
string(6) "Merger"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(528)
}
[1]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(450)
}
[2]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(433)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(306)
}
[4]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(301)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(241)
}
[6]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(238)
}
[7]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(232)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(194)
}
[9]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(189)
}
[10]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(179)
}
[11]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(163)
}
[12]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(161)
}
[13]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(160)
}
[14]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(142)
}
[15]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(133)
}
[16]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(130)
}
[17]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(125)
}
[18]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(119)
}
[19]=>
array(2) {
["name"]=>
string(8) "spin-off"
["count"]=>
int(114)
}
[20]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(112)
}
[21]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(108)
}
[22]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(98)
}
[23]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(98)
}
[24]=>
array(2) {
["name"]=>
string(12) "Staff hiring"
["count"]=>
int(85)
}
[25]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(85)
}
[26]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(81)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(80)
}
[28]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(78)
}
[29]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(74)
}
}
}
a26d9-us-avexis-inc
Novartis Gene Therapies, Inc.
Location
Illinois
Founded
2010-02-28
Website
https://www.novartis.com
Articles
7824 Articles
Category
Pharmaceutical Preparations
Description
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP
The takeover offer from Novartis to the German drug researcher Morphosys was met with approval. The board of directors and supervisory board of Morphosys have recommended acceptance to the shareholders.
Novartis published the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG.
The Federal Cartel Office has approved the planned takeover of all shares in MorphoSys AG, based in Planegg near Munich, by Novartis AG (Switzerland) in the preliminary review process under merger control law.
By Jay Ezrielev1 I. Introduction The newly finalized U.S. Department of Justice( DOJ) and the Federal Trade Commission( FTC) Merger Guidelines have excluded one of the most controversial statements of the draft Merger Guidelines.2 That statement is:“ The antitrust laws reflect a preference for
After Novartis's takeover offer to Morphosys, other German companies could find themselves in the sights of corporate hunters. BÖRSE ONLINE presents five candidates
Drugmaker Novartis AG ( NOVN.CH ) is in advanced talks to take over MorphoSys AG ( MOR.DE ), two people familiar with the matter told Reuters on Monday.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
